Ursodeoxycholic acid in the treatment of liver diseases (Q36727616)

15 August 2017

1 reference

title

Ursodeoxycholic acid in the treatment of liver diseases (English)

1 reference

15 August 2017

Saksena S

1

1 reference

PMCID

2431224

15 August 2017

Tandon RK

series ordinal

2

1 reference

PMCID

2431224

15 August 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

Postgraduate Medical Journal

15 August 2017

1 reference

15 August 2017

73

1 reference

15 August 2017

856

1 reference

15 August 2017

75-80

1 reference

Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

A possible role of ursodeoxycholic acid in liver transplantation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

The syndrome of primary sclerosing cholangitis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Formation of ursodeoxycholic acid from chenodeoxycholic acid in the human colon: studies of the role of 7-ketolithocholic acid as an intermediate.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Caloric content of a meal affects duration but not contractile pattern of duodenal motility in man.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Ursodeoxycholic acid increases low-density lipoprotein binding, uptake and degradation in isolated hamster hepatocytes

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Colonic absorption of unconjugated bile acids: perfusion studies in man

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431224

Cirrhosis as a consequence of graft-versus-host disease

20 October 2018

1 reference

12 December 2020

Modulation of low density lipoprotein receptor activity by bile acids: differential effects of chenodeoxycholic and ursodeoxycholic acids in the hamster

1 reference

12 December 2020

Ileal excretion of bile acids: Comparison with biliary bile composition and effect of ursodeoxycholic acid treatment

1 reference

12 December 2020

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

12 December 2020

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

12 December 2020

Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid

1 reference

12 December 2020

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

12 December 2020

A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis

1 reference

12 December 2020

Graft-versus-host disease

1 reference

12 December 2020

Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study

1 reference

12 December 2020

[Ursodeoxycholic acid for the treatment of chronic diseases of the liver. Short-term results]

1 reference

12 December 2020

Metabolism of ursodeoxycholic acid in man

1 reference

12 December 2020

Tauroursodeoxycholate prevents taurocholate induced cholestasis

1 reference

12 December 2020

The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease

1 reference

12 December 2020

Therapeutic effect of ursodeoxycholic acid on early-stage primary biliary cirrhosis

1 reference

12 December 2020

Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation

1 reference

12 December 2020

Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy

1 reference

12 December 2020

Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

12 December 2020

[Factors influencing the effect of ursodeoxycholic acid therapy in chronic hypertransaminasemia]

1 reference

12 December 2020

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

12 December 2020

Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis

1 reference

12 December 2020

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

12 December 2020

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up

1 reference

12 December 2020

Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC

1 reference

12 December 2020

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

12 December 2020

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

12 December 2020

A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: a role for PKC

1 reference

12 December 2020

Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

12 December 2020

Identifiers

DOI

10.1136/PGMJ.73.856.75

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

PMCID

2431224